Sumatriptan-naproxen sodium for menstrual migraine and dysmenorrhea: Satisfaction, productivity, and functional disability outcomes

Headache

Volumn 51, Issue 5, 2011, Pages 664-673

  Cady, Roger K ^a   Diamond, Merle L ^b,c   Diamond, Michael P ^d   Ballard, Jeanne E ^e   Lener, Michelle E ^f   Dorner, Deborah P ^g   Derosier, Frederick J ^f   McDonald, Susan A ^f   White, Jonathan ^f   Runken, M Chris ^f  

^a HEADACHE CARE CENTER   (United States)

^b DIAMOND HEADACHE CLINIC   (United States)

^c ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^d WAYNE STATE UNIVERSITY   (United States)

^e Northern Indiana Women's Health Research   (United States)

^f GLAXOSMITHKLINE   (United States)

^g Scientific Therapeutics Information Inc   (United States)

Author keywords

dysmenorrhea; menstrual migraine; sumatriptan naproxen sodium

Indexed keywords

NAPROXEN PLUS SUMATRIPTAN; PLACEBO;

ADULT; ARTICLE; DISABILITY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DYSMENORRHEA; EVALUATION; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; LEISURE; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; MENSTRUAL MIGRAINE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PATIENT SATISFACTION; PRIORITY JOURNAL; PRODUCTIVITY; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SINGLE DRUG DOSE; WORK;

ADULT; ANALGESICS; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; DYSMENORRHEA; FEMALE; HUMANS; MIGRAINE DISORDERS; NAPROXEN; PATIENT SATISFACTION; PREMENSTRUAL SYNDROME; SUMATRIPTAN;

EID: 79955380412     PISSN: 00178748     EISSN: 15264610     Source Type: Journal    
DOI: 10.1111/j.1526-4610.2011.01894.x     Document Type: Article

References (19)

1. Dawood MY,. Primary dysmenorrhea: Advances in pathogenesis and management. Obstet Gynecol. 2006; 108: 428-441. (Pubitemid 44305687)
2. Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M,. Prevalence and burden of migraine in the United States: Data from the American Migraine Study II. Headache. 2001; 41: 646-657. (Pubitemid 32777747)
3. Mannix LK,. Menstrual-related pain conditions: Dysmenorrhea and migraine. J Womens Health. 2008; 17: 879-889.
4. Smith TR, Sunshine A, Stark SR, Littlefield DE, Spruill SE, Alexander WJ,. Sumatriptan and naproxen sodium for the acute treatment of migraine. Headache. 2005; 45: 983-991.
5. Brandes JL, Kudrow D, Stark SR, et al,. Sumatriptan-naproxen sodium for acute treatment of migraine: A randomized trial. JAMA. 2007; 297: 1443-1454. (Pubitemid 46556470)
6. Silberstein S, Mannix LK, Goldstein J, et al,. Multimechanistic (sumatriptan-naproxen) early intervention for the acute treatment of migraine. Neurology. 2008; 71: 114-121.
7. Lipton RB, Dodick DW, Adelman JU, et al,. Consistency of response to sumatriptan/naproxen sodium in a placebo-controlled, crossover study. Cephalalgia. 2009; 29: 826-836.
8. Mathew NT, Landy S, Stark S, et al,. Fixed-dose sumatriptan and naproxen in poor responders to triptans with a short half-life. Headache. 2009; 49: 971-982.
9. Landy S, DeRossett SE, Rapoport A, et al,. Two double-blind, multicenter, randomized, placebo-controlled, single-dose studies of sumatriptan/naproxen sodium in the acute treatment of migraine: Function, productivity, and satisfaction outcomes. MedGenMed. 2007; 9: 53.
10. Smith T, Blumenthal H, Diamond M, et al,. Sumatriptan/naproxen sodium for migraine: Efficacy, health related quality of life, and satisfaction outcomes. Headache. 2007; 47: 683-692. (Pubitemid 46733717)
11. Taylor FR, Heiring J, Messina E, et al,. Sumatriptan/naproxen sodium as early intervention for migraine: Effects on functional ability, productivity, and satisfaction in 2 randomized controlled trials. J Clin Outcomes Manag. 2007; 14: 195-204. (Pubitemid 46753878)
12. TM and naproxen for acute migraine treatment. Cephalalgia. 2007; 27: 702.
13. Kimel M, Hsieh R, McCormack J, Burch SP, Revicki DA,. Validation of the revised Patient Perception of Migraine Questionnaire (PPMQ-R): Measuring satisfaction with acute migraine treatment in clinical trials. Cephalalgia. 2008; 28: 510-523. (Pubitemid 351502541)
14. Revicki DA, Kimel M, Beusterien K, et al,. Validation of the revised Patient Perception of Migraine Questionnaire: Measuring satisfaction with acute migraine treatment. Headache. 2006; 46: 240-252.
15. Burton WN, Landy SH, Downs KE, Runken MC,. The impact of migraine and the effect of migraine treatment on workplace productivity in the United States and suggestions for future research. Mayo Clin Proc. 2009; 84: 436-445.
16. Lipton RB, Liberman JN, Kolodner KB, Bigal ME, Dowson A, Stewart WF,. Migraine headache disability and health-related quality-of-life: A population-based case-control study from England. Cephalalgia. 2003; 23: 441-450. (Pubitemid 36776060)
17. Mannix LK, Martin VT, Cady RK, et al,. Combination treatment for menstrual migraine and dysmenorrhea using sumatriptan-naproxen: Two randomized controlled trials. Obstet Gynecol. 2009; 114: 106-113.
18. Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders (second edition). Cephalalgia. 2004; 24 (Suppl. 1): 1-160.
19. Winner P, Cady RK, Ruoff GE, et al,. Twelve-month tolerability and safety of sumatriptan-naproxen sodium for the treatment of acute migraine. Mayo Clin Proc. 2007; 82: 61-68. (Pubitemid 46036322)